Latest news with #DistributionAgreement
Yahoo
15-05-2025
- Business
- Yahoo
CAPREIT Renews At-The-Market Equity Program
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust ('CAPREIT') (TSX: announced today that it has renewed its at-the-market equity program (the 'ATM Program') allowing CAPREIT to issue units of CAPREIT ('Trust Units') up to an aggregate sale price of $300 million from treasury to the public from time to time, at its sole discretion. Any Trust Units sold in the ATM Program will be sold directly through the Toronto Stock Exchange (the 'TSX') or on any other permitted marketplace at the prevailing market price at the time of sale. The ATM Program provides CAPREIT with additional financing flexibility, should it be required in the future. The volume and timing of distributions under the ATM Program, if any, will be determined at CAPREIT's sole discretion. CAPREIT intends to use the net proceeds from the ATM Program, if any, for future investments, repayment of indebtedness, and for general business purposes. As Trust Units sold in the ATM Program will be distributed at the prevailing market price at the time of sale, prices may vary among purchasers during the period of distribution. There is no certainty that any Trust Units will be offered or sold under the ATM Program. Distributions of the Trust Units through the ATM Program, if any, will be made pursuant to the terms of an equity distribution agreement dated May 15, 2025 (the 'Equity Distribution Agreement') with TD Securities Inc. (the 'Agent'). The ATM Program will be effective until June 15, 2027, unless terminated prior to such date by CAPREIT or otherwise in accordance with the terms of the Equity Distribution Agreement. The ATM Program is being established pursuant to a prospectus supplement dated May 15, 2025 (the 'Prospectus Supplement') to CAPREIT's short form base shelf prospectus (the 'Shelf Prospectus') dated May 15, 2025, both of which have been filed with securities regulatory authorities in each of the provinces of Canada. CAPREIT's previous at-the-market equity program, which commenced on February 22, 2024, ceased upon the establishment of the renewed ATM Program. The Prospectus Supplement, the Shelf Prospectus and the Equity Distribution Agreement are available on SEDAR+ at under CAPREIT's profile. This press release does not constitute an offer to sell securities, nor is it a solicitation of an offer to buy securities, in any jurisdiction in which such offer, solicitation or sale is unlawful. This press release is not an offer of securities for sale in the United States ('U.S.'). The securities being offered have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and accordingly are not being offered for sale and may not be offered, sold or delivered, directly or indirectly within the U.S., its possessions and other areas subject to its jurisdiction or to, or for the account or for the benefit of a U.S. person, except pursuant to an exemption from the registration requirements of that Act. ABOUT CAPREITCAPREIT is Canada's largest publicly traded provider of quality rental housing. As at March 31, 2025, CAPREIT owns approximately 46,800 residential apartment suites and townhomes, that are well-located across Canada and the Netherlands, with a total fair value of approximately $14.9 billion, excluding approximately $12.5 million of assets held for sale. For more information about CAPREIT, its business and its investment highlights, please visit our website at and our public disclosures which can be found under our profile at CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTSCertain statements contained in this press release constitute forward-looking statements within the meaning of applicable Canadian securities laws which reflect CAPREIT's current expectations and projections about future results. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'outlook', 'objective', 'may', 'will', 'expect', 'intent', 'estimate', 'anticipate', 'believe', 'consider', 'should', 'plans', 'predict', 'estimate', 'forward', 'potential', 'could', 'likely', 'approximately', 'scheduled', 'forecast', 'variation' or 'continue', or similar expressions suggesting future outcomes or events, and which include, without limitation, the aggregate value of Trust Units which may be issued pursuant to the ATM Program and CAPREIT's expected use of the net proceeds of the ATM Program, if any. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Actual results and developments may differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. Any number of factors could cause actual results to differ materially from these forward-looking statements. Although CAPREIT believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Such forward-looking statements are based on a number of assumptions that may prove to be incorrect. Accordingly, readers should not place undue reliance on forward-looking statements. Forward looking statements in this press release are subject to certain risks and uncertainties that could result in actual results differing materially from these forward-looking statements. These risks and uncertainties are more fully described in regulatory filings that can be obtained on SEDAR+ at Except as specifically required by applicable Canadian securities law, CAPREIT does not undertake any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. These forward-looking statements should not be relied upon as representing CAPREIT's views as of any date subsequent to the date of this press release. For more information, please contact: CAPREITMr. Mark KenneyPresident and Chief Executive Officer(416) 861-9404 CAPREITMr. Stephen CoChief Financial Officer(416) 306-3009 CAPREITMr. Julian SchonfeldtChief Investment Officer(647) 535-2544 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-04-2025
- Business
- Yahoo
JFT Strategies Fund Renews At-The-Market Equity Program
NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO, April 02, 2025--(BUSINESS WIRE)--CI Global Asset Management ("CI GAM") announces that JFT Strategies Fund (TSX: (the "Fund") has renewed its at-the-market equity program (the "ATM Program"). The ATM Program allows the Fund to issue Class A units of the Fund ("Units") having an aggregate sale price of up to $100,000,000, to the public from time to time, at the discretion of CI GAM. Any Units issued under the ATM Program will be sold at the prevailing market price at the time of sale through the Toronto Stock Exchange ("TSX") or any other marketplace in Canada on which the Units are listed, quoted or otherwise traded. This ATM Program replaces the prior at-the-market equity program of the Fund, which commenced on February 27, 2023 and expired on March 22, 2025. The volume and timing of distributions under the ATM Program, if any, will be determined at the Manager's sole discretion. The ATM Program will be effective until April 30, 2027, unless terminated prior to such date by the Fund. The Fund intends to use the proceeds from the ATM Program in accordance with the Fund's investment objectives, investment strategies and investment restrictions. Sales of the Units through the ATM Program will be made pursuant to the terms of an equity distribution agreement entered into by the Fund, CI GAM, and Timelo Investment Management Inc., as portfolio manager of the Fund (the "Equity Distribution Agreement"), dated April 2, 2025 with National Bank Financial Inc. (the "Agent"). Sales of the Units will be made by way of "at-the-market distributions" as defined in National Instrument 44-102 Shelf Distributions on the TSX or on any marketplace for the Units in Canada. Since the Units will be distributed at prevailing market prices at the time of the sale, prices may vary among purchasers during the period of distribution. The ATM Program is being offered pursuant to a prospectus supplement dated April 2, 2025 to the Fund's short form base shelf prospectus dated March 31, 2025. Copies of the Fund's prospectus supplement and short form base shelf prospectus and the applicable Equity Distribution Agreement may be obtained from your registered financial advisor using the contact information for such advisor, or from representatives of the Agent, and are available on SEDAR+ at About JFT Strategies Fund The Fund's investment objective is to maximize total return on investment to its holders while seeking to mitigate market risk and volatility by investing in an actively managed portfolio of long and short positions in any one or a combination of equities, debt securities or other securities. The Fund will seek to generate positive returns by selecting what Timelo Investment Management Inc. ("Timelo"), the portfolio manager (the "Portfolio Manager"), believes to be superior quality investments for long positions and inferior quality investments for short positions. The Fund's net exposure (long versus short) varies depending upon the Portfolio Manager's view of macroeconomic and other factors. The Portfolio Manager may also make selective use of derivatives and other securities in order to increase returns and/or mitigate the downside risk of one or more of the portfolio's investments. The lead portfolio manager of the Fund is Jean-François Tardif, CFA, President of Timelo. Mr. Tardif founded Timelo in 2011 to serve the needs of investors who were seeking an investment solution which provided an attractive risk-adjusted return while being uncorrelated with equity markets. About CI Global Asset Management CI Global Asset Management ("CI GAM") is one of Canada's largest investment management companies. It offers a wide range of investment products and services and is on the web at CI GAM is a subsidiary of CI Financial Corp. (TSX: CIX), an integrated global asset and wealth management company with approximately $529.4 billion in assets as at December 31, 2024. Forward-Looking Statements Certain statements included in this news release constitute forward-looking statements, including, but not limited to, those identified by the expressions "expect", "intend", "will" and similar expressions to the extent they relate to the Fund. The forward-looking statements are not historical facts but reflect the Fund's and/or CI GAM's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations, including, but not limited to, market factors. Although the Fund and/or CI GAM believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, readers are cautioned not to place undue reliance on such statements due to the inherent uncertainty therein. The Fund and/or CI GAM undertakes no obligation to update publicly or otherwise revise any forward-looking statement or information whether as a result of new information, future events or other factors which affect this information, except as required by law. The short form base shelf prospectus and the prospectus supplement containing important detailed information about the securities being offered have been filed with securities commissions or similar authorities in each of the provinces and territories of Canada. Copies of the Equity Distribution Agreement, the short form base shelf prospectus and the prospectus supplement may be obtained from the Agent. Investors should read the short form base shelf prospectus and the prospectus supplement before making an investment decision. This communication is intended for informational purposes only. You will usually pay brokerage fees to your dealer if you purchase or sell Units of the Fund on the TSX. If the Units are purchased or sold on the TSX, investors may pay more than the current net asset value when buying Units of the Fund and may receive less than the current net asset value when selling them. There are ongoing fees and expenses associated with owning Units of the Fund. An investment fund must prepare disclosure documents that contain key information about the fund. You can find more detailed information about the Fund in these documents. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated. The Fund is managed by CI Global Asset Management. CI Global Asset Management is a registered business name of CI Investments Inc. ©CI Investments Inc. 2025. All rights reserved. View source version on Contacts Murray OxbyVice-President, Corporate CommunicationsCI Global Asset Management416-681-3254moxby@ Sign in to access your portfolio
Associated Press
01-03-2025
- Business
- Associated Press
SHAREHOLDER ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ('Revance' or the 'Company') (NASDAQ: RVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the 'Class Period'). If you are an investor in Revance and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than March 4, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. Revance is a biotechnology company and the distributor of certain dermal filler products pursuant to an exclusive distribution agreement with Teoxane SA. On August 12, 2024, Revance issued a press release announcing that the Company had entered into a merger agreement with Crown Laboratories ('Crown'). Under the terms of the agreement, the press release indicated that Crown would commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share (the 'Tender Offer'). Then, on September 23, 2024, Revance disclosed that it 'received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA.' Due to the dispute with Teoxane, the Company advised that Crown's Tender Offer had been delayed until at least October 4, 2024. On this news, the price of Revance stock fell $.445 per share, or 7.66%, to close at $5.365 per share on September 23, 2024. Then, on December 9, 2024, the Company disclosed that Crown and Revance had amended their merger agreement, and that Crown would commence a tender offer on December 12, 2024 to acquire all outstanding shares of Revance common stock for $3.10 per share, more than 50% lower than the original purchase price. On this news, the price of Revance stock fell $.79 per share, or 20.68%, to close at $3.03 per share on December 9, 2024. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Revance was in material breach of the Distribution Agreement; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; and (iii) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 Laurence D. King 1999 Harrison Street, Suite 1560 Oakland, California 94612
Associated Press
25-02-2025
- Business
- Associated Press
Securities Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox Before Deadline on March 4, 2025
NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ('Revance' or the 'Company') (NASDAQ: RVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the 'Class Period'). If you are an investor in Revance and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than March 4, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. Revance is a biotechnology company and the distributor of certain dermal filler products pursuant to an exclusive distribution agreement with Teoxane SA. On August 12, 2024, Revance issued a press release announcing that the Company had entered into a merger agreement with Crown Laboratories ('Crown'). Under the terms of the agreement, the press release indicated that Crown would commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share (the 'Tender Offer'). Then, on September 23, 2024, Revance disclosed that it 'received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA.' Due to the dispute with Teoxane, the Company advised that Crown's Tender Offer had been delayed until at least October 4, 2024. On this news, the price of Revance stock fell $.445 per share, or 7.66%, to close at $5.365 per share on September 23, 2024. Then, on December 9, 2024, the Company disclosed that Crown and Revance had amended their merger agreement, and that Crown would commence a tender offer on December 12, 2024 to acquire all outstanding shares of Revance common stock for $3.10 per share, more than 50% lower than the original purchase price. On this news, the price of Revance stock fell $.79 per share, or 20.68%, to close at $3.03 per share on December 9, 2024. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Revance was in material breach of the Distribution Agreement; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; and (iii) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King 1999 Harrison Street, Suite 1560 Oakland, California 94612
Associated Press
13-02-2025
- Business
- Associated Press
Kaplan Fox Alerts Revance Therapeutics Investors to a Securities Class Action Lawsuit - Deadline is March 4, 2025
NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ('Revance' or the 'Company') (NASDAQ: RVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the 'Class Period'). If you are an investor in Revance and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than March 4, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. Revance is a biotechnology company and the distributor of certain dermal filler products pursuant to an exclusive distribution agreement with Teoxane SA. On August 12, 2024, Revance issued a press release announcing that the Company had entered into a merger agreement with Crown Laboratories ('Crown'). Under the terms of the agreement, the press release indicated that Crown would commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share (the 'Tender Offer'). Then, on September 23, 2024, Revance disclosed that it 'received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA.' Due to the dispute with Teoxane, the Company advised that Crown's Tender Offer had been delayed until at least October 4, 2024. On this news, the price of Revance stock fell $.445 per share, or 7.66%, to close at $5.365 per share on September 23, 2024. Then, on December 9, 2024, the Company disclosed that Crown and Revance had amended their merger agreement, and that Crown would commence a tender offer on December 12, 2024 to acquire all outstanding shares of Revance common stock for $3.10 per share, more than 50% lower than the original purchase price. On this news, the price of Revance stock fell $.79 per share, or 20.68%, to close at $3.03 per share on December 9, 2024. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Revance was in material breach of the Distribution Agreement; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; and (iii) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 1999 Harrison Street, Suite 1560 Oakland, California 94612
